TMS Prior Authorization Guide for OCD: Requirements by Payer (2025–2026)

Transcranial magnetic stimulation for obsessive-compulsive disorder is a legitimate, FDA-cleared treatment — and one of the most poorly navigated prior authorization processes in psychiatry. The reason is structural: TMS for OCD is a medical benefit procedure authorization (not a pharmacy benefit), requires demonstrating treatment- resistant OCD specifically, and hinges on device and payer distinctions that most authorization specialists don’t know exist.

This guide covers what makes TMS for OCD PAs different, which payers cover it, and what documentation each one requires.

Freshness notice: TMS coverage policies for OCD are still evolving rapidly. Aetna does not cover TMS for OCD as of this guide’s review. Medicare coverage is limited to specific geographic regions. Requirements below reflect policies as of mid-2026. Verify against each payer’s current published clinical policy before submitting.

The Device Gate: FDA Clearance for OCD, Not Coil Shape

TMS for OCD is not the same as TMS for depression — even on the same machine.

The FDA clearance history: Brainsway received the first FDA clearance specifically for OCD in 2018 (De Novo DEN170078), using the H7 deep coil system targeting the medial prefrontal cortex and anterior cingulate cortex. Since then, several additional devices have received 510(k) clearances for OCD based on equivalency, including:

• MagVenture D-B80 coil (~2020)
• Apollo TMS (K243539)
• BTL-99-OC (K230657)
• CloudTMS for OCD (K221129)
• Magstim Horizon/Inspire (K243869)

The coverage gate is FDA clearance for the OCD indication, not coil type. A standard figure-8 rTMS device used for depression (NeuroStar, Magstim) is not covered for OCD if it hasn’t been cleared for that indication. A figure-8 device that IS cleared for OCD (MagVenture D-B80) is coverable. The question to verify: does the specific device in the practice hold FDA clearance for OCD?

Who Covers TMS for OCD — and Who Doesn’t

Before reviewing PA criteria, understand the coverage landscape:

What Is Treatment-Resistant OCD?

Diagnosis: DSM-5 OCD criteria, ICD-10 F42.x.

Y-BOCS documentation: The Yale-Brown Obsessive Compulsive Scale must be administered at the start of any TMS course. Most payers require Y-BOCS documentation to establish severity and to assess response at the end of the course. Cigna’s policy (EN0383) requires Y-BOCS measurement but does not set a minimum entry score; some other plans and the Clinical TMS Society use ≥20 as a standard moderate-severity threshold. Document the Y-BOCS with subscale scores.

Prior medication failures:

Adequate trial definition (Cigna EN0383, verbatim): Therapeutic dose for at least 8 weeks with no significant Y-BOCS reduction, OR documented intolerance or contraindication. Document the dose, duration, and outcome for each trial separately.

ERP/Psychotherapy requirement: Exposure and Response Prevention is the gold-standard behavioral treatment for OCD and a prerequisite at all covering payers. Requires a trained OCD therapist — general CBT is typically insufficient. Document provider, session count, and dates. If ERP is inaccessible, document the barrier explicitly.

CPT Codes and Benefit Structure

Medical benefit (Part B for Medicare) — not pharmacy benefit.

Standard protocol: Cigna (EN0383) specifies 30–36 treatments per course (5/week for 6–7 weeks). Premera specifies 36 sessions + 6 taper sessions.

Ordering clinician: Board-certified or board-eligible psychiatrist, or an advanced- practice psychiatric nurse with TMS training. A primary care order will be denied.

Payer-Specific PA Requirements

Cigna / Evernorth

Source: Cigna Policy EN0383, effective 3/15/2026

Coverage: Yes. Cigna is the most clearly documented covering commercial payer.

Criteria (all required):

• Age ≥18
• DSM OCD diagnosis
• Failure of ≥2 psychopharmacologic OCD medication trials (therapeutic dose × ≥8 weeks each, no significant Y-BOCS reduction), OR documented intolerance/contraindication
• Adequate trial of evidence-based psychotherapy (ERP/CBT) without significant improvement
• Y-BOCS administered at baseline and end of each course
• FDA-cleared device for OCD indication

Sessions per course: 30–36 treatments.

Re-treatment criteria: Response in the prior course defined as ≥30% Y-BOCS improvement, sustained for ≥2 months before retreatment.

PA requirement change: Cigna/Evernorth dropped prior authorization for TMS (including OCD) for in-network providers effective approximately March 2026. Out-of-network providers still require PA. Medical necessity criteria still apply — absence of PA doesn’t mean absence of medical necessity review at claims.

UnitedHealthcare / Optum

Coverage: Likely yes, but criteria are in the Optum Behavioral Clinical Policy — not the public UHC medical policy (Policy 2026T0536W, eff. 2/1/2026), which explicitly redirects behavioral indications to the Optum behavioral portal. The Optum behavioral policy is behind the authenticated Provider Express portal.

Action required: Log into Provider Express at myoptum.com/provider and pull the current “Transcranial Magnetic Stimulation” behavioral clinical policy before submitting a TMS-for-OCD PA. Do not rely on the public-facing UHC medical policy for OCD criteria.

The expected framework based on the Clinical TMS Society criteria (which most covering payers reference): ≥2 medication failures, ERP trial, psychiatrist order, FDA-cleared device. Verify exact thresholds from the Optum portal.

Aetna

Coverage: No. Aetna Clinical Policy Bulletin CPB 0469 classifies TMS for OCD as experimental, investigational, and unproven. Aetna’s position cites insufficient evidence that TMS is superior to placebo for OCD — a rationale that predates the Brainsway pivotal trial data but remains Aetna’s current policy.

There is no PA pathway for Aetna OCD TMS. The drug is not excluded — the procedure is categorically non-covered. Submitting a PA will generate a non-covered benefit denial, not a medical necessity denial. Appeals on clinical grounds will not succeed under the current policy.

For Aetna patients: Explore alternative approaches — ERP intensification, medication augmentation, or clinical trial enrollment. Check if the patient has a secondary insurer. Watch for Aetna CPB 0469 updates; Aetna does revise CPBs quarterly.

BlueCross / BCBS

BCBS is not one payer. OCD TMS coverage varies by licensee:

Plans that cover OCD:

• Premera Blue Cross (WA/AK) — effective Feb 2023; 36 sessions; ≥2 medication failures + psychotherapy; FDA-cleared device
• BCBS HCSC (IL/TX/NM/OK/MT) — covers dTMS for OCD with standard criteria

Plans that do not cover OCD:

• Anthem BCBS — TMS covered for MDD only; OCD not covered

Other BCBS plans: Pull the specific regional plan’s TMS clinical policy. There is no shared BCBS OCD position.

Humana

Humana’s commercial coverage for TMS OCD varies by plan. Humana has been expanding TMS behavioral health coverage in Medicare Advantage products. Verify the specific plan’s behavioral health benefit document before assuming coverage.

Medicare Part B

There is no National Coverage Determination (NCD) for TMS — not for depression and not for OCD. TMS coverage under Medicare is entirely governed by Local Coverage Determinations (LCDs) issued by each Medicare Administrative Contractor.

Most MACs: LCD covers TMS for MDD only. OCD is explicitly excluded from most active LCDs.

Exception — Palmetto GBA (LCD L33398, effective March 13, 2022): Palmetto GBA issued an LCD covering Brainsway Deep TMS for OCD in its jurisdiction: Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

Palmetto OCD criteria:

• DSM OCD diagnosis
• ≥2 medication trial failures
• Psychotherapy trial (ERP)
• FDA-cleared device
• Re-treatment: ≥30% Y-BOCS improvement sustained ≥1 month

For Medicare patients outside the Palmetto region: TMS for OCD is not covered. This is not a PA issue — it’s a benefit-existence issue. Check the patient’s MAC (find via cms.gov/medicare/coding-billing/medicare-contractor-provider-enrollment/find-your- medicare-administrative-contractor) before initiating treatment.

Medicare Advantage: Some MA plans exceed original Medicare’s coverage. Check the specific MA plan’s behavioral health benefit.

Tips for First-Pass Approval

1. Verify your device’s FDA clearance for OCD — not just “TMS device” but specifically cleared for the OCD indication. List the device name and clearance in the PA.

2. Two medication failures, documented individually. Drug name, dose, duration in weeks, outcome (Y-BOCS at end, or reason for intolerance). Reviewers count trials; make each one unambiguous.

3. Y-BOCS at baseline before PA submission. Document subscale scores, not just total.

4. ERP: name the provider, session count, and dates. If inaccessible, document the barrier (distance, waitlist, cost) specifically.

5. For Cigna: In-network providers don’t need PA for TMS post-March 2026. Confirm network status before submitting one unnecessarily.

6. For UHC: Log into Provider Express for the Optum behavioral policy before submitting — don’t use the public-facing medical policy.

7. For Aetna: Do not submit. Document the non-coverage for the patient’s records and redirect to alternatives.

8. For Medicare: Confirm Palmetto GBA jurisdiction before ordering. If outside Palmetto territory, TMS for OCD is not covered.

When the PA Fails

Sources

• FDA De Novo DEN170078 — Brainsway Deep TMS H7, OCD indication (2018)
• Cigna / Evernorth Policy EN0383, effective 3/15/2026
• Aetna Clinical Policy Bulletin CPB 0469 — Transcranial Magnetic Stimulation
• Palmetto GBA LCD L33398 — Transcranial Magnetic Stimulation, effective 3/13/2022
• Carmi L et al., Am J Psychiatry 2019;176(11):931-938 — Brainsway OCD pivotal trial
• APA Practice Guideline for OCD (2023)
• Yale-Brown Obsessive Compulsive Scale — Goodman et al., Arch Gen Psychiatry 1989

PA requirements update frequently. This guide was last reviewed June 2026. Always verify against each payer’s current published clinical policy before submitting.

Artificer Health automates prior authorization end-to-end — including behavioral health procedure authorizations for TMS and other psychiatric treatments. Learn more at artificerhealth.com